太平洋生物科学公司（Pacific Biosciences of California，股票代码：PACB）在周三夜盘交易中股价大幅下跌8.62%，引发市场广泛关注。这一显著跌幅与公司最新发布的第三季度财务报告密切相关。
根据太平洋生物科学公司发布的2025年第三季度财报，公司实现调整后毛利润1620万美元，但每股收益为-0.13美元。这一业绩数据表明，尽管公司在毛利润方面有所表现，但仍未能扭亏为盈，整体财务状况不及市场预期。负的每股收益凸显了公司在盈利能力方面仍面临严峻挑战。
分析人士指出，公司持续亏损的状况是导致股价大跌的主要原因。投资者对太平洋生物科学公司的财务健康状况和未来增长前景产生了担忧，从而引发了这波夜盘抛售潮。该公司能否改善其财务状况、提升盈利能力，将成为投资者密切关注的焦点。后市走势如何，还需进一步观察公司的业务发展策略及市场反应。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.